Integrated analyses of translatome and proteome identify the rules of translation selectivity in RPS14-deficient cells

Haematologica. 2021 Mar 1;106(3):746-758. doi: 10.3324/haematol.2019.239970.

Abstract

In ribosomopathies, the Diamond-Blackfan anemia (DBA) or 5q- syndrome, ribosomal protein (RP) genes are affected by mutation or deletion, resulting in bone marrow erythroid hypoplasia. Unbalanced production of ribosomal subunits leading to a limited ribosome cellular content regulates translation at the expense of the master erythroid transcription factor GATA1. In RPS14-deficient cells mimicking 5q- syndrome erythroid defects, we show that the transcript length, codon bias of the coding sequence (CDS) and 3’UTR (untranslated region) structure are the key determinants of translation. In these cells, short transcripts with a structured 3’UTR and high codon adaptation index (CAI) showed a decreased translation efficiency. Quantitative analysis of the whole proteome confirmed that the post-transcriptional changes depended on the transcript characteristics that governed the translation efficiency in conditions of low ribosome availability. In addition, proteins involved in normal erythroid differentiation share most determinants of translation selectivity. Our findings thus indicate that impaired erythroid maturation due to 5q- syndrome may proceed from a translational selectivity at the expense of the erythroid differentiation program, and suggest that an interplay between the CDS and UTR may regulate mRNA translation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia, Diamond-Blackfan* / genetics
  • Anemia, Macrocytic*
  • Humans
  • Proteome / genetics
  • Ribosomal Proteins* / deficiency
  • Ribosomal Proteins* / genetics
  • Ribosomes / genetics

Substances

  • Proteome
  • RPS14 protein, human
  • Ribosomal Proteins

Grants and funding

Funding: This study was funded by INSERM, by the Institut National du Cancer (INCa) and the Direction Générale de l’Offre de Soins (DGOS) of the French Ministry of Social Affairs and Health through the Programme Hospitalier de Recherche Clinique (PHRC MDS-04: INCa-DGOS_5480). SLG was the recipient of a PhD funding from the Laboratory of Excellence on red cells GR-Ex.